7 active not recruiting, 5 completed, 5 unknown, 3 recruiting. 23 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Active not recruiting 7, Completed 5, Unknown 5, Recruiting 3, Not yet recruiting 2, Withdrawn 1 |
| Phase 1 | 6 | Active not recruiting 3, Unknown 2, Not yet recruiting 1 |
Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL Celecoxib Combined with R-CHOP, R-CHOP - Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive | Phase 2 | Recruiting | Sun Yat-sen University | 60 | 2026-03-06 | 2026-07-22 |
| Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 122 | 2026-02-28 | 2026-02-10 |
| Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL ZCR-CHOP, R-CHOP - BTK Inhibitors, Histone Deacetylase Inhibitor | Phase 2 | Not yet recruiting | Li Zhiming | 128 | 2025-06-01 | 2025-03-24 |
| Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial) Orelabrutinib Oral Tablet, R-CHOP Protocol - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Sun Yat-sen University | 39 | 2024-11-01 | 2024-10-22 |
| Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) Selinexor Oral Tablet [Xpovio], R-CHOP Protocol - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Sun Yat-sen University | 42 | 2024-08-01 | 2026-02-12 |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 54 | 2022-11-01 | 2023-12-14 |
| Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) R-CHOP, R-CHOP + acalabrutinib - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | University Hospital Southampton NHS Foundation Trust | 453 | 2021-10-19 | 2026-04-30 |
| Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma Acalabrutinib, R-CHOP chemotherapy - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | University Health Network, Toronto | 105 | 2021-03-01 | 2026-06-12 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Biosciences Japan GK | 72 | 2020-12-15 | 2026-10-21 |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 543 | 2020-11-03 | 2026-11-03 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 78 | 2020-08-20 | 2026-11-04 |
| Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL Copanlisib, R-CHOP Chemotherapy - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | University Hospital Muenster | 62 | 2020-06-19 | 2026-07-30 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma Pembrolizumab, R-CHOP Protocol - B Cell Lymphoma, Lymphoma | Phase 2 | Active not recruiting | University of Chicago | 51 | 2019-08-29 | 2025-06-08 |
| A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome Venetoclax, DA-EPOCH-R, R-CHOP - Richter Syndrome | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 69 | 2017-03-08 | 2026-07-10 |
| Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma R-CHOP - Diffuse Large B-cell Lymphoma, HIV | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 39 | 2016-03-01 | 2022-10-28 |
| Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC) - Mantle Cell Lymphoma, Untreated | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 49 | 2015-12-14 | 2024-08-30 |
| Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Duvelisib, Rituximab, R-CHOP - Lymphoma | Phase 2 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL R-CHOP - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Fudan University | 196 | 2013-02-01 | 2013-03-05 |
| Erythropoietin for Management of Anemia Caused by Chemotherapy Darbepoetin alfa, R-CHOP - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Kosin University Gospel Hospital | 53 | 2012-09-01 | 2020-02-20 |
Showing 20 of 23. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (16) · Lymphoma (4) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, Follicular (2) · Pyloric Stenosis, Hypertrophic (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1)
Sun Yat-sen University (5) · Genmab (2) · CTI BioPharma (1) · Dana-Farber Cancer Institute (1) · Fudan University (1) · Heidelberg University (1) · Huiqiang Huang (1) · Incyte Biosciences Japan GK (1) · Kosin University Gospel Hospital (1) · Li Zhiming (1) · Memorial Sloan Kettering Cancer Center (1) · Pusan National University Hospital (1) · SecuraBio (1) · UNC Lineberger Comprehensive Cancer Center (1) · University Health Network, Toronto (1)
China (8) · United States (6) · Germany (3) · Canada (2) · France (2) · Italy (2) · Japan (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Czechia (1) · Denmark (1) · Finland (1) · Malawi (1) · Netherlands (1)
Andrew Davies (1) · Anita Kumar, MD (1) · Anthony D. Ho, Ph.D., Prof. (1) · Gabor Jurida, M.D. (1) · Hagop Youssoufian, MD (1) · Ho-Jin Ho-Jin (1) · Justin Kline, MD (1) · Matthew Painschab, MD (1) · Matthew S. Davids, MD, MMSc (1) · Prof. Georg Lenz, MD (1) · QingQing Cai, MD. PhD. (1) · Rong Tao, MD. (1) · Ye Guo, MD (1) · Yi Xia, MD. PhD. (1) · Zhiming Li, M.D. (1)
PMID 23946328, PMID 34022150, PMID 34788401, PMID 35418080, PMID 39792928, PMID 40632620, PMID 40920572, PMID 41563911, PMID 41784015, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129
2015 (1), 2023 (1), K01TW009488 (1), R21CA180815 (1)